In its biggest investment so far, CordenPharma is earmarking €900 million ($982 million) over the next three years to expand its peptide platform capacity in the US and Europe to meet rising GLP-1 manufacturing demand.
The Swiss CDMO has “played a pretty significant role” in GLP-1 manufacturing so far and is now further expanding capacity, CEO Michael Quirmbach told Endpoints News in an interview.
CordenPharma will build a third facility at its only North American site in Boulder, CO, as well as add peptide manufacturing lines at one of two of its existing facilities on the same site. Its existing facilities in Colorado currently manufacture peptides, oligonucleotides, lipids and APIs for clinical and commercial use.
The CDMO will also build a new site from scratch in “the heart of Europe” for large-scale clinical and commercial peptide manufacturing for GLP-1 drugs. CordenPharma will reveal the location of the European site in the next three months, Quirmbach said.
All construction will be finished by 2027 and will go online in 2028, Quirmbach said. Around 400 new jobs will be added across the US and European expansions, he added. Both the US and European expansions will have capacity to make long and short peptides.
The expansion is a result of increasing demand for GLP-1 drugs, where CordenPharma has secured several undisclosed multiyear contracts worth around €3 billion to make peptides for GLP-1s. The company presently has a total of 10 manufacturing sites in Europe, plus the site in Colorado.
According to the CDMO, the added capacity announced Tuesday will help it reach its goal of making €1 billion in sales for its peptide offerings by 2028, including sales from APIs as well as oral and injectable peptides. CordenPharma made €880 million ($960 million) in sales for the 2023 fiscal year. It has over 3,000 employees.
Michael Quirmbach
“We are honored by the trust our customers have placed in us to deliver expert outsourcing for large multiyear contracts, and our team is proud to contribute decades of peptide manufacturing experience towards these transformative new medicines,” CEO Michael Quirmbach said in a statement.
CordenPharma has made earlier moves in expanding its footprint. In April, it expanded its site in Frankfurt, Germany for early clinical-stage peptide APIs. In September 2023, it upgraded both of its Colorado facilities.
“CordenPharma has a unique opportunity to reinforce its leadership position in peptides with unmatched capacity and performance in large-scale manufacturing,” said Judith Charpentier, head of healthcare at Astorg, a private equity firm that took part in buying CordenPharma in May 2022.
https://endpts.com/cordenpharma-injects-e900m-to-boost-glp-1-manufacturing-in-us-and-europe/

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services

AAV GMP Services
